Media stories about Erytech Pharma (NASDAQ:ERYP) have trended somewhat positive recently, Accern Sentiment reports. The research firm scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Erytech Pharma earned a coverage optimism score of 0.17 on Accern’s scale. Accern also gave news stories about the company an impact score of 45.6386172806161 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Shares of Erytech Pharma (ERYP) traded up $1.13 during trading hours on Thursday, hitting $19.75. 20,000 shares of the company were exchanged, compared to its average volume of 26,000. The company has a current ratio of 10.67, a quick ratio of 10.65 and a debt-to-equity ratio of 0.03. Erytech Pharma has a 52 week low of $17.50 and a 52 week high of $30.56.

A number of equities analysts recently weighed in on the stock. Cowen assumed coverage on shares of Erytech Pharma in a report on Tuesday, December 5th. They issued an “outperform” rating on the stock. JMP Securities assumed coverage on shares of Erytech Pharma in a report on Friday, December 1st. They issued an “outperform” rating and a $43.00 price target on the stock.

COPYRIGHT VIOLATION NOTICE: This news story was first published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of U.S. & international copyright legislation. The original version of this news story can be viewed at

Erytech Pharma Company Profile

Erytech Pharma SA, also known as ERYTECH Pharma, is a France-based biopharmaceutical company developing medicinal products mainly in oncology, hematology and immunology fields of business. The Company offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells.

Receive News & Ratings for Erytech Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Erytech Pharma and related companies with Analyst Ratings Network's FREE daily email newsletter.